Filing Flows › Maxcyte (MXCT) › Q1 2026 › vs Q4 2025
Maxcyte (MXCT) Q1 2026 vs Q4 2025 (quarter over quarter)
Maxcyte's revenue rose $2.4M (+32%) from $7.3M in Q4 2025 to $9.7M in Q1 2026. The biggest changes: Licenses +$3.0M (+118%); Product sales −$514K (-12%); Assay and other service revenue −$127K (-21%).
Maxcyte, Q1 2026: revenue $9.7M (-7% year over year), operating margin -64.1%, net loss $4.8M, operating cash flow −$8.2M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Licenses | $5.5M | $2.5M | $3.0M | +118% |
| Product sales | $3.6M | $4.2M | −$514K | -12% |
| Assay and other service revenue | $482K | $609K | −$127K | -21% |
| Revenue | $9.7M | $7.3M | $2.4M | +32% |
| Other income, net | $1.4M | $1.6M | −$195K | -12% |
| Net loss | $4.8M | $9.6M | −$4.8M | -51% |
| Costs & expenses | $15.8M | $18.5M | −$2.7M | -15% |
| Operating costs | $15.8M | $18.5M | −$2.7M | -15% |
| Cost of revenue | $1.6M | $1.6M | −$41K | -3% |
| Research & development | $3.9M | $3.3M | $522K | +16% |
| Sales & marketing | $3.4M | $3.5M | −$76K | -2% |
| General & admin | $6.0M | $5.5M | $484K | +9% |
| Other operating costs | $1.0M | $4.6M | −$3.6M | -78% |
| Operating cash sources | $10.4M | $4.5M | $5.9M | +132% |
| Depreciation & amortization | $1.0M | $1.1M | −$25K | -2% |
| Share-based compensation | $1.1M | $706K | $435K | +62% |
| Cash used in operations | $8.2M | $2.7M | $5.5M | +204% |
| Net loss absorbed | $4.8M | $9.6M | −$4.8M | -51% |
| Working capital & other | $5.6M | −$5.1M | $10.7M | — |
Questions
How much did Maxcyte's revenue grow quarter over quarter in Q1 2026?
Maxcyte's revenue rose $2.4M (+32%) from $7.3M in Q4 2025 to $9.7M in Q1 2026.
What drove Maxcyte's revenue change in Q1 2026?
Licenses +$3.0M (+118%); Product sales −$514K (-12%); Assay and other service revenue −$127K (-21%).